i-Sens: CareSens Air Continuous blood sugar monitoring device

Main article: Blood sugar (glucose) monitoring

2023: Approved for use in Korea

South Korea's i-Sens said it has received regulatory approval to apply CareSens Air - its first continuous blood sugar monitoring (CGM) device. This became known on September 28, 2023.

𝓲

evercare.ru

CareSens Air became the fourth CGM-class product to win approval in Korea, behind products from Medtronic, Abbott and Dexcom.

A continuous glucose monitor is a body-worn device that continuously monitors blood sugar levels. It can usually be worn for up to a week and does not require finger pricks to control sugar.

In March 2023, i-SENS and the firm Kakao Healthcare signed a memorandum of understanding to work together to treat chronic diseases using their platforms and product development skills. Under the agreement, i-SENS will continue to build products for the treatment and care of patients, and Kakao Healthcare - digital solutions and platforms for healthcare. In addition, the two companies will continue to work together to improve convenience for consumers and enter the international market.

According to i-SENS, in Korea, CareSens Air has the longest usage time (15 days) and is the smallest and lightest CGM-class device.

Without a separate receiver, the device sends blood glucose readings from the sensor to a smartphone app every five minutes. It also displays 24-hour trends in blood sugar levels. To improve the accuracy of the results, the device provides the possibility of calibration by the user.

The system is sold in one-off packages, so consumers who need short-term monitoring can purchase it without much financial difficulty.

In the near future, i-SENS intends to introduce CGM after full-scale mass production begins^[1] is^[2].

Notes